[go: up one dir, main page]

NO20005411L - Antipicornavirusforbindelser, deres fremstilling og anvendelse - Google Patents

Antipicornavirusforbindelser, deres fremstilling og anvendelse

Info

Publication number
NO20005411L
NO20005411L NO20005411A NO20005411A NO20005411L NO 20005411 L NO20005411 L NO 20005411L NO 20005411 A NO20005411 A NO 20005411A NO 20005411 A NO20005411 A NO 20005411A NO 20005411 L NO20005411 L NO 20005411L
Authority
NO
Norway
Prior art keywords
compounds
antipicornavirus
preparation
peptido
formula
Prior art date
Application number
NO20005411A
Other languages
English (en)
Other versions
NO20005411D0 (no
Inventor
Peter S Dragovich
Joseph T Marakovits
Thomas J Prins
Jayashree Girish Tikhe
Stephen E Webber
Ru Zhou
Jr Theodore O Johnson
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of NO20005411D0 publication Critical patent/NO20005411D0/no
Publication of NO20005411L publication Critical patent/NO20005411L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Peptido- og peptidoetterligningsforbindelser med formelen:. hvor formel-variablene er som definert i beskrivelsen, hemmer eller blokkerer fordelaktig den biologiske aktiviteten til picornaviral 3C protease. Disse forbindelser, så vel som farmasøytiske preparater inneholdende disse forbindelser, er nyttige for behandling av pasienter eller verter infisert med én eller flere picomavirus, så som RVP. Mellomprodukter og syntese-metoder for fremstilling av slike forbindelser er også fremlagt.
NO20005411A 1998-04-30 2000-10-27 Antipicornavirusforbindelser, deres fremstilling og anvendelse NO20005411L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8382898P 1998-04-30 1998-04-30
US9835898P 1998-08-28 1998-08-28
PCT/US1999/000260 WO1999057135A1 (en) 1998-04-30 1999-01-05 Antipicornaviral compounds, their preparation and use

Publications (2)

Publication Number Publication Date
NO20005411D0 NO20005411D0 (no) 2000-10-27
NO20005411L true NO20005411L (no) 2000-10-27

Family

ID=26769788

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005411A NO20005411L (no) 1998-04-30 2000-10-27 Antipicornavirusforbindelser, deres fremstilling og anvendelse

Country Status (33)

Country Link
US (3) US6531452B1 (no)
EP (1) EP1073672B1 (no)
JP (1) JP2003526600A (no)
KR (1) KR20010043004A (no)
CN (1) CN1198838C (no)
AP (1) AP2000001934A0 (no)
AT (2) ATE308557T1 (no)
AU (1) AU768539B2 (no)
BG (1) BG104899A (no)
BR (1) BR9910573A (no)
CA (1) CA2326763A1 (no)
DE (2) DE69928140D1 (no)
DK (1) DK1073672T3 (no)
EA (1) EA003856B1 (no)
EE (1) EE200000621A (no)
ES (1) ES2205760T3 (no)
GE (1) GEP20022824B (no)
HR (1) HRP20000623A2 (no)
HU (1) HUP0400624A2 (no)
IL (1) IL138609A0 (no)
IS (1) IS5633A (no)
LT (1) LT4846B (no)
LV (1) LV12666B (no)
NO (1) NO20005411L (no)
NZ (1) NZ507633A (no)
OA (1) OA11503A (no)
PL (1) PL351250A1 (no)
PT (1) PT1073672E (no)
SI (1) SI20428A (no)
SK (1) SK284714B6 (no)
TR (1) TR200003159T2 (no)
WO (1) WO1999057135A1 (no)
YU (1) YU66000A (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003856B1 (ru) 1998-04-30 2003-10-30 Агурон Фармасьютикалз, Инк. Антипикорнавирусные композиции, их получение и применение
US6774243B2 (en) 1999-08-24 2004-08-10 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
US6355807B1 (en) 1999-08-24 2002-03-12 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
PE20010517A1 (es) * 1999-08-24 2001-05-16 Agouron Pharma Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves
PA8507801A1 (es) 1999-12-03 2002-08-26 Agouron Pharma Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis
PA8515201A1 (es) 2000-04-14 2002-10-24 Agouron Pharma Compuestos y composiciones antipicornavirales; sus usos farmaceuticos y los materiales para su sintesis
JP2004503533A (ja) * 2000-06-14 2004-02-05 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗ピコルナウイルス化合物及び組成物、その医薬的使用、並びにその合成のための物質
WO2004093860A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Inhibitors of sars related coronavirus proteinase
US20040235952A1 (en) * 2003-05-05 2004-11-25 Agouron Pharmaceuticals, Inc. Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
US7462594B2 (en) 2003-12-31 2008-12-09 Taigen Biotechnology Co., Ltd. Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
CA2550515A1 (en) * 2003-12-31 2005-07-21 Taigen Biotechnology Protease inhibitors
CN100363346C (zh) * 2004-10-22 2008-01-23 清华大学 冠状病毒主蛋白酶的小分子抑制剂、制备方法及其应用
US7893657B2 (en) * 2006-12-19 2011-02-22 Anand Kumar Chavakula Multi-power charger and battery backup system
KR100891699B1 (ko) 2007-04-10 2009-04-03 광주과학기술원 7-아미노-4-((s)-3-(4-플루오로페닐)-2-((r)-3-메틸-2-(5-메틸이소옥사졸-3-카복사미도)부탄아미도)프로판아미도)-7-옥소-2-헵테노에이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 및 치료용 약학적 조성물
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
AU2009250295B2 (en) 2008-05-21 2014-05-01 Genesis Technologies Limited Selective caspase inhibitors and uses thereof
US9045524B2 (en) 2009-05-21 2015-06-02 Novagenesis Foundation Selective caspase inhibitors and uses thereof
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
ES2665301T3 (es) 2011-04-15 2018-04-25 Genesis Technologies Limited Inhibidores selectivos de cisteína proreasa y usos de los mismos
CN102838523A (zh) * 2011-06-23 2012-12-26 南开大学 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途
CN103145608B (zh) * 2011-12-07 2015-09-02 南开大学 抗肠病毒71(ev71)己内酰胺类化合物及其制备方法和用途
RU2518314C2 (ru) * 2012-08-30 2014-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
CN110105348A (zh) * 2019-03-08 2019-08-09 南开大学 新型迈克尔受体类肠病毒71型抑制剂的制备及用途
AU2020289560A1 (en) * 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
JP2021138694A (ja) 2020-03-06 2021-09-16 ファイザー・インク SARS−CoV−2複製を阻害し、コロナウイルス疾患2019を処置する方法
CN115697328A (zh) * 2020-03-23 2023-02-03 约翰·M.H.·格雷格 抗病毒化合物及其给药方法
WO2022156692A1 (zh) * 2021-01-22 2022-07-28 中国人民解放军军事科学院军事医学研究院 一种环肽类病毒蛋白酶抑制剂,其制备方法,及其在抗病毒药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652676A (en) 1985-05-06 1987-03-24 General Foods Corporation L-aminodicarboxylic acid alkenes
WO1992022570A1 (en) 1991-06-14 1992-12-23 Chiron Corporation Inhibitors of picornavirus proteases
US5374623A (en) 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US5514778A (en) 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
IT1269511B (it) 1994-05-17 1997-04-01 Univ Degli Studi Milano Derivati di acidi ammino-solfonici , loro impiego nella sintesi di pseudopeptidi e procedimento per la loro preparazione
US5498616A (en) 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
IT1281031B1 (it) 1995-11-17 1998-02-11 Carlo Chiaves Struttura prefabbricata per la realizzazione di opere costruite a cielo aperto, particolarmente per cavalcavia autostradali,
TW442452B (en) 1996-03-01 2001-06-23 Akzo Nobel Nv Serine protease inhibitors having an alkynylamino side chain
US5856530A (en) 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
DE69733137T2 (de) * 1996-05-14 2006-03-02 Agouron Pharmaceuticals, Inc., San Diego Inhibitoren von picornavirus 3c protease und verfahren zur herstellung und verwendung
WO1997049668A1 (en) 1996-06-13 1997-12-31 Smithkline Beecham Corporation Inhibitiors of cysteine protease
US6020371A (en) 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use
PT975588E (pt) * 1997-03-28 2004-02-27 Agouron Pharma Compostos antipicornavirais, composicoes que os contem e metodos para a sua utilizacao
US6331554B1 (en) 1997-03-28 2001-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
US5962487A (en) 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
EA003856B1 (ru) 1998-04-30 2003-10-30 Агурон Фармасьютикалз, Инк. Антипикорнавирусные композиции, их получение и применение
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
DE60014670T2 (de) 1999-08-04 2006-03-09 Agouron Pharmaceuticals, Inc., San Diego Antipicornavirale verbindungen und zusammensetzungen, ihre pharmazeutische verwendung, und materialien für ihre synthese
IL147862A0 (en) 1999-08-24 2002-08-14 Agouron Pharma Process and intermediates for the preparation os isoxazolecaroxamides and analogues
PE20010517A1 (es) 1999-08-24 2001-05-16 Agouron Pharma Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves
PA8507801A1 (es) 1999-12-03 2002-08-26 Agouron Pharma Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis

Also Published As

Publication number Publication date
NO20005411D0 (no) 2000-10-27
HK1034722A1 (en) 2001-11-02
LV12666B (lv) 2001-11-20
US20030130204A1 (en) 2003-07-10
CN1198838C (zh) 2005-04-27
WO1999057135A1 (en) 1999-11-11
DE69910762T2 (de) 2004-03-11
TR200003159T2 (tr) 2001-09-21
HRP20000623A2 (en) 2001-04-30
PT1073672E (pt) 2004-01-30
OA11503A (en) 2004-05-10
EA200001133A1 (ru) 2001-08-27
DE69928140D1 (de) 2005-12-08
BG104899A (en) 2001-08-31
NZ507633A (en) 2003-10-31
CA2326763A1 (en) 1999-11-11
IL138609A0 (en) 2001-10-31
GEP20022824B (en) 2002-10-25
IS5633A (is) 2000-09-22
SK284714B6 (sk) 2005-09-08
AP2000001934A0 (en) 2000-12-31
EP1073672A1 (en) 2001-02-07
EA003856B1 (ru) 2003-10-30
CN1311793A (zh) 2001-09-05
LT4846B (lt) 2001-10-25
EP1073672B1 (en) 2003-08-27
US6531452B1 (en) 2003-03-11
JP2003526600A (ja) 2003-09-09
LT2000109A (en) 2001-05-25
DE69910762D1 (de) 2003-10-02
US20060046966A1 (en) 2006-03-02
ATE248186T1 (de) 2003-09-15
HUP0400624A2 (hu) 2004-06-28
ES2205760T3 (es) 2004-05-01
AU768539B2 (en) 2003-12-18
DK1073672T3 (da) 2003-12-08
SI20428A (sl) 2001-06-30
KR20010043004A (ko) 2001-05-25
AU2028799A (en) 1999-11-23
SK16042000A3 (sk) 2001-05-10
ATE308557T1 (de) 2005-11-15
BR9910573A (pt) 2001-01-16
LV12666A (en) 2001-05-20
EE200000621A (et) 2002-06-17
YU66000A (sh) 2003-12-31
PL351250A1 (en) 2003-04-07
US6995142B2 (en) 2006-02-07

Similar Documents

Publication Publication Date Title
NO20005411L (no) Antipicornavirusforbindelser, deres fremstilling og anvendelse
DK1206484T3 (da) Antipicornavirale forbindelser og sammensætninger, deres farmaceutiske anvendelser og materialer til deres syntese
BR9813651A (pt) Compostos antipicornavirais e métodos para o seu uso e preparação
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
AP2003002915A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
NO20022589L (no) Anti-picornavirus-forbindelser og -preparater, deres farmasöytiske anvendelse og materialer for syntese av dem
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
SE0001899D0 (sv) New compounds
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
SE0301446D0 (sv) New Compounds
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
BR0008416A (pt) Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila
DE60101372D1 (de) Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
WO2001079167A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
NO20055624L (no) Tropanderivater og deres anvendelse som Ace-inhibitorer
DK0975588T3 (da) Antipicornavirale forbindelser, sammensætninger indeholdende dem og fremgangsmåder til deres anvendelse
NO20062533L (no) 5-fluor, 5-klor- og cyanopyridin-2-yl-tetrazoler som ligander for den metabotrofe glutamatreseptor-5
WO2001096297A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
EP1329457A3 (en) Antipicornaviral compounds, their preparation and use
WO2002023784A3 (en) Cysteine protease inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application